Antifibrotic Therapy Management by Advanced Practice Providers

Management of antifibrotic therapies by advanced practice providers is of great importance in the management of interstitial lung disease (ILD), specifically in patients with idiopathic pulmonary fibrosis (IPF) and those with progressive pulmonary fibrosis (PPF). Given that antifibrotic agents have become a cornerstone for managing disease progression, advanced practice providers (APPs) have a pivotal role in the initiation of therapy, assessment of treatment responses, resolution of therapy-related adverse events, and long-term adherence to therapy.

Management of antifibrotic therapy by advanced practice providers involves a pre-treatment structured evaluation, a post-treatment lab monitoring regimen, individualized adherence strategies, and a collaborative, multidisciplinary approach to optimize the safety and efficacy of the therapy.

Through the ILD Community Network, APPs can build on their clinical knowledge, enhance their antifibrotic therapy management skills, and ultimately, improve the management of patients with fibrotic lung disease.

The central role of advanced practice providers in antifibrotic therapy management is to mitigate the risk of disease progression in patients with fibrotic interstitial lung disease. The various ways in which advanced practice providers convey safe and evidence-based care include therapy initiation, laboratory monitoring, management of adverse effects, and long-term therapy optimization.

Advanced practice providers receive online courses, clinical updates, and professional networking opportunities through the ILD Community Network, enabling them to confidently manage antifibrotic therapy and enhance the quality of life of patients with progressive fibrotic lung disease.

#antifibrotictherapymanagement #apps #advancedpracticeproviders #ild